Hopes For Glaxo’s MAGE-A3 Vaccine Grow Dim As Trial Misses Endpoint
This article was originally published in The Pink Sheet Daily
Executive Summary
Glaxo’s vaccine fails co-primary endpoint in Phase III DERMA study of melanoma – trial is allowed to continue but hopes for success are not high. Top-line release raises specter that drug could become yet another failed cancer vaccine.